相关实验视频

Updated: Jan 18, 2026

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions

Published on: October 21, 2022

循环RNA剖析揭示了丰富的circPTK2,通过调节miR-1-5p/ACVR2B/StarD13轴,它有助于通过everolimus诱导的内皮细胞功能障碍

Yixin Zhao¹, Jiangrong Wang¹, Xiaomeng Jia¹

¹Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.

Acta cardiologica

|May 28, 2025

概括

循环RNA PTK2 (circPTK2) 恶化了由药物释放支架组件everolimus诱导的内皮功能障碍. 准circPTK2/miR-1-5p/ACVR2B/StarD13通路可能为内置支架缩提供新的治疗方法.

科学领域:

心血管生物学心血管生物学
分子生物学分子生物学
基因组学就是基因组学.

背景情况:

药物排泄支架 (DES) 使用mTOR抑制剂,可以促进支架内新动脉样硬化 (ISNA) 和晚期支架内静止 (ISR).
循环RNAs (circRNAs) 与各种疾病有关,但它们在ISNA中的作用尚不清楚.

研究的目的:

为了研究circRNAs在everolimus诱导的内皮功能障碍中的作用.
阐明在ISNA中circRNA参与背后的分子机制.

主要方法:

在经过埃弗罗利斯治疗的人类静脉内皮细胞 (HUVECs) 中进行RNA测序以分析circRNAs.
定量实时PCR测量circRNA,miR-1-5p和目标基因表达.
细胞测试 (增殖,迁移,细胞亡,透性) 来评估circPTK2的功能.
生物信息学,双光酶和功能救援实验,以确定分子相互作用.

主要成果:

在Everolimus治疗的HUVEC中,CircPTK2的调节显著上升.
冲击CircPTK2可以逆转everolimus诱导的内皮功能障碍,而过度表达会使其恶化.
电路PTK2作为一个miR-1-5p海绵,上调ACVR2B和StarD13的表达.
炎症条件调节了circPTK2,miR-1-5p和ACVR2B/StarD13的表达.

结论:

通过miR-1-5p/ACVR2B/StarD13通路,CircPTK2在everolimus诱导的内皮功能障碍中发挥着至关重要的作用.
这一途径代表了DES植入后晚期ISR的潜在治疗标.

关键词:

电路PTK2 电路PTK2 晚期的静脉支架复缩.这是一架米R-1战斗机.内皮质功能障碍在内皮质功能障碍每个olimus排泄的支架.

更多相关视频

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Identification of Circular RNAs using RNA Sequencing

Identification of Circular RNAs using RNA Sequencing

Published on: November 14, 2019

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...